ABSTRACT
Introduction
At the 65th American Society of Hematology (ASH) 2023 Annual Meeting, the latest advancements in CD20×CD3 BsAbs for B-cell lymphoma (BCL) were highlighted, particularly in relapsed/refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL).
Areas covered
This summary highlights some of the major studies on CD20×CD3 BsAbs for BCL.
Expert Opinion/Commentary
CD20×CD3 is the most widely studied BsAb, with promising results in patients with R/R DLBCL and R/R FL ≥ two prior lines of systemic therapy. Trials with the first line of B-cell lymphoma also revealed promising results. Hopefully, BsAb monotherapy or BsAb-containing regimens may become the standard therapy in patients with FL and DLBCL.
Abbreviations
ASH | = | American Society of Hematology |
BCL | = | B-cell lymphoma |
BsAbs | = | bispecific antibodies |
CAR T-cell | = | chimeric antigen receptor T-cell |
CMR | = | complete metabolic response |
CR | = | complete response |
CRS | = | cytokine release syndrome |
DLBCL | = | diffuse large B cell lymphoma |
FL | = | follicular lymphoma |
LBCL | = | large B-cell lymphoma |
ORR | = | overall response rate |
OS | = | overall survival |
R/R | = | relapsed or refractory |
Declaration of interest
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
Author contribution statement
J Yu designed and directed the manuscript. H Sun, H Xing and L Han wrote the manuscript draft. Y Liu and J Yu revised the manuscript. Y Song and Z Jiang provided resources. All authors reviewed and approved the final manuscript.
Acknowledgments
The authors would like to thank all the patients and their families for participating in clinical trials testing the drugs mentioned in this review.
Correction Statement
This article has been corrected with minor changes. These changes do not impact the academic content of the article.